

American Cancer Society, Inc.

**Consolidated Financial Statements and Supplementary Information; and
Reports and Schedules Related to Title 2 U.S. Code of
Federal Regulations Part 200, Uniform Administrative Requirements,
Cost Principles, and Audit Requirements for Federal Awards (Uniform
Guidance)**

As of and for the Years Ended December 31, 2021 and 2020

American Cancer Society, Inc.
Contents
December 31, 2021 and 2020

	Page(s)
Report of Independent Auditors	1-3
Consolidated Financial Statements	
Consolidated Balance Sheets	4
Consolidated Statements of Activities	5-6
Consolidated Statements of Functional Expenses	7-8
Consolidated Statements of Cash Flows.....	9
Stewardship Focused Disclosures	10-18
Other Required Disclosures	19-41
 Supplementary Information	
Schedule of Expenditures of Federal Awards.....	42-43
Notes to Schedule of Expenditures of Federal Awards.....	44
 Reports and Schedules Required by the Uniform Guidance	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	45-46
Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance.....	47-49
Schedule of Findings and Questioned Costs.....	50-51



Ernst & Young LLP
Suite 1000
55 Ivan Allen Jr. Boulevard
Atlanta, GA 30308

Tel: +1 404 874 8300
Fax: +1 404 817 5589
ey.com

Report of Independent Auditors

Management and The Board of Directors
American Cancer Society, Inc.

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of the American Cancer Society, Inc. (“the Society”), which comprise the consolidated balance sheets as of December 31, 2021 and 2020, and the related consolidated statements of activities, functional expenses, and cash flows for the years then ended and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the American Cancer Society at December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards (Government Auditing Standards)*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Society, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Society’s ability to continue as a going concern for one year after the date that the financial statements are issued.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Society's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The *Schedule of Expenditures of Federal Awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management



and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated June 9, 2022 on our consideration of the Society's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Society's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Society's internal control over financial reporting and compliance.

Ernst + Young LLP

June 9, 2022

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2021 and 2020
(In Thousands)

Assets		
	2021	2020
Current assets:		
Cash and cash equivalents	\$ 44,845	\$ 47,469
Investments	138,488	132,840
Receivables, net	35,087	39,949
Prepaid expenses	10,356	11,038
Bequests receivable	114,255	76,563
Total current assets	343,031	307,859
Receivables, net	38,782	37,667
Other assets	7,389	7,776
Gift annuity investments	41,716	39,460
Investments	810,712	699,287
Beneficial interests in trusts	406,638	371,852
Fixed assets, net	270,575	279,093
Total assets	\$ 1,918,843	\$ 1,742,994
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and other accrued expenses	\$ 54,547	\$ 63,327
Research and other program grants payable	84,432	75,275
Employee retirement benefits	2,793	2,940
Debt	2,036	2,227
Other liabilities	3,084	1,774
Total current liabilities	146,892	145,543
Research and other program grants payable	114,241	90,414
Employee retirement benefits	167,853	210,479
Other liabilities	3,009	7,569
Debt	35,479	46,982
Gift annuity obligations	13,614	13,972
Total liabilities	481,088	514,959
Commitments and contingencies		
Net assets:		
Without donor restrictions:	665,930	506,973
With donor restrictions:	771,825	721,062
Total net assets	1,437,755	1,228,035
Total liabilities and net assets	\$ 1,918,843	\$ 1,742,994

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2021
(In Thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Our mission program and mission support expenses were:			
Mission program services:			
Patient support	\$ 294,894	\$ -	\$ 294,894
Discovery	151,160	-	151,160
Advocacy	35,477	-	35,477
Total mission program services	<u>481,531</u>	<u>-</u>	<u>481,531</u>
Mission support services:			
Management and general	24,997	-	24,997
Fund-raising	95,420	-	95,420
Total mission support services	<u>120,417</u>	<u>-</u>	<u>120,417</u>
Total mission program and mission support services expenses	<u>601,948</u>	<u>-</u>	<u>601,948</u>
Our mission program and mission support expenses were funded by:			
Support from the public:			
Special events	97,535	56,243	153,778
Contributions	158,813	106,811	265,624
Bequests	154,177	45,466	199,643
Contributed services, merchandise and other in-kind contributions	25,565	22,578	48,143
Other	14,045	1,903	15,948
Total support from the public	<u>450,135</u>	<u>233,001</u>	<u>683,136</u>
Investment income	22,587	16,162	38,749
Change in value of split-interest agreements	4,329	39,164	43,493
Grants and contracts from government agencies	5,671	442	6,113
Other (losses)	(2,454)	(980)	(3,434)
Total revenues, gains and other support	<u>480,268</u>	<u>287,789</u>	<u>768,057</u>
Use of amounts restricted by donors for specified purpose or time	237,026	(237,026)	-
Change in net assets prior to impact of retirement plan liability	<u>115,346</u>	<u>50,763</u>	<u>166,109</u>
Net (decrease) in retirement plan liability	<u>(43,611)</u>	<u>-</u>	<u>(43,611)</u>
Change in net assets	<u>158,957</u>	<u>50,763</u>	<u>209,720</u>
Net assets, beginning of period	<u>506,973</u>	<u>721,062</u>	<u>1,228,035</u>
Net assets, end of period	<u>\$ 665,930</u>	<u>\$ 771,825</u>	<u>\$ 1,437,755</u>

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED DECEMBER 31, 2020
(In Thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Our mission program and mission support expenses were:			
Mission program services:			
Patient support	\$ 316,342	\$ -	\$ 316,342
Discovery	93,780	-	93,780
Advocacy	32,377	-	32,377
Total mission program services	<u>442,499</u>	<u>-</u>	<u>442,499</u>
Mission support services:			
Management and general	35,551	-	35,551
Fund-raising	104,198	-	104,198
Total mission support services	<u>139,749</u>	<u>-</u>	<u>139,749</u>
Total mission program and mission support services expenses	<u>582,248</u>	<u>-</u>	<u>582,248</u>
Our mission program and mission support expenses were funded by:			
Support from the public:			
Special events	97,596	39,068	136,664
Contributions	148,554	84,602	233,156
Bequests	97,092	40,243	137,335
Contributed services, merchandise and other in-kind contributions	15,192	24,904	40,096
Other	12,066	479	12,545
Total support from the public	<u>370,500</u>	<u>189,296</u>	<u>559,796</u>
Investment income	46,823	21,051	67,874
Change in value of split-interest agreements	3,061	15,892	18,953
Grants and contracts from government agencies	5,436	355	5,791
Other gains (losses)	745	(345)	400
Total revenues, gains and other support	<u>426,565</u>	<u>226,249</u>	<u>652,814</u>
Use of amounts restricted by donors for specified purpose or time	190,108	(190,108)	-
Change in net assets prior to impact of retirement plan liability	<u>34,425</u>	<u>36,141</u>	<u>70,566</u>
Net increase in retirement plan liability	1,287	-	1,287
Change in net assets	<u>33,138</u>	<u>36,141</u>	<u>69,279</u>
Net assets, beginning of period	473,835	684,921	1,158,756
Net assets, end of period	<u>\$ 506,973</u>	<u>\$ 721,062</u>	<u>\$ 1,228,035</u>

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2021
(In Thousands)

	Mission program			Mission support			Total mission support	Total before exchange expenses	Exchange expenses (see note 6)	Total
	Patient support	Discovery	Advocacy	Total mission program	Management and general	Fundraising				
Mission program and mission support expenses										
Personnel costs	\$145,325	\$ 21,177	\$ 22,341	\$ 188,843	\$ 10,327	\$ 60,994	\$ 71,321	\$ 260,164	\$ 7,774	\$267,938
Professional fees and contractual services	13,561	5,806	4,020	23,387	8,808	4,895	13,703	37,090	2,069	39,159
Grants for mission program services	13,501	110,372	132	124,005	-	-	-	124,005	-	124,005
Education and marketing	57,892	694	4,072	62,658	878	13,041	13,919	76,577	2,759	79,336
Direct assistance to patients	1,616	-	-	1,616	-	-	-	1,616	-	1,616
Meetings and travel	1,950	131	142	2,223	61	1,229	1,290	3,513	10,837	14,350
Postage and shipping	8,197	244	57	8,498	829	3,714	4,543	13,041	42	13,083
Hope Lodge and community facilities	22,293	2,925	2,153	27,371	403	3,783	4,186	31,557	7,666	39,223
Technology	15,984	7,106	1,595	24,685	1,108	5,239	6,347	31,032	148	31,180
Depreciation and amortization	10,521	2,082	507	13,110	343	1,185	1,528	14,638	38	14,676
Miscellaneous	4,054	623	458	5,135	2,240	1,340	3,580	8,715	1,991	10,706
Cost of donated merchandise sold	-	-	-	-	-	-	-	-	22,813	22,813
Total mission program, mission support, and exchange expenses	\$294,894	\$151,160	\$ 35,477	\$ 481,531	\$ 24,997	\$ 95,420	\$120,417	\$ 601,948	\$ 56,137	\$658,085

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED DECEMBER 31, 2020
(In Thousands)

	Mission program			Mission support			Total mission support	Total before exchange expenses	Exchange expenses (see note 6)	Total
	Patient support	Discovery	Advocacy	Total mission program	Management and general	Fundraising				
Mission program and mission support expenses										
Personnel costs	\$177,385	\$ 22,954	\$ 22,549	\$ 222,888	\$ 16,026	\$ 72,358	\$ 88,384	\$ 311,272	\$ 7,067	\$318,339
Professional fees and contractual services	17,655	8,441	2,864	28,960	7,490	7,143	14,633	43,593	387	43,980
Grants for mission program services	6,975	50,673	167	57,815	-	-	-	57,815	-	57,815
Education and marketing	40,146	760	1,341	42,247	2,496	9,292	11,788	54,035	2,480	56,515
Direct assistance to patients	7,223	-	-	7,223	-	-	-	7,223	-	7,223
Meetings and travel	2,869	313	408	3,590	226	1,216	1,442	5,032	2,719	7,751
Postage and shipping	5,782	141	36	5,959	2,214	3,517	5,731	11,690	49	11,739
Hope Lodge and community facilities	29,604	3,576	3,023	36,203	1,237	3,763	5,000	41,203	7,379	48,582
Technology	13,274	4,446	1,594	19,314	2,149	4,263	6,412	25,726	23	25,749
Depreciation and amortization	11,580	1,689	96	13,365	616	1,681	2,297	15,662	2	15,664
Miscellaneous	3,849	787	299	4,935	3,097	965	4,062	8,997	1,532	10,529
Cost of donated merchandise sold	-	-	-	-	-	-	-	-	14,686	14,686
Total mission program, mission support, and exchange expenses	\$316,342	\$ 93,780	\$ 32,377	\$ 442,499	\$ 35,551	\$ 104,198	\$139,749	\$ 582,248	\$ 36,324	\$618,572

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31, 2021 and 2020
(In Thousands)

Cash flows from operating activities	2021	2020
Cash received from (used in):		
Special events	\$ 168,424	\$ 143,010
Contributions	265,001	231,549
Bequests	175,256	136,649
Other support from the public	16,867	12,545
Government grants	5,796	5,453
Interest and dividends on investments, net	19,382	20,866
Other revenue	4,480	8,832
Program services	33,351	14,930
Interest on debt	(862)	(824)
Employees and suppliers	(464,030)	(499,113)
Direct assistance	(1,616)	(3,513)
Retirement plan contributions	(20,045)	(7,269)
Grants for mission program services	(91,022)	(96,573)
Net cash received from (used in) operating activities	<u>110,982</u>	<u>(33,458)</u>
Cash flows from investing activities		
Purchase of fixed assets	(19,048)	(31,891)
Proceeds from disposal of fixed assets	11,882	21,630
Support from the public restricted for fixed asset acquisition	4,416	13,159
Purchases of investments	(1,595,428)	(779,434)
Proceeds from maturities or sale of investments	1,491,528	757,388
Net cash used in investing activities	<u>(106,650)</u>	<u>(19,149)</u>
Cash flows from financing activities		
Payments made to annuitants	(1,541)	(1,699)
Proceeds from annuitants	823	1,355
Support from the public restricted for long-term Investment	5,455	11,361
Payments on debt	(11,693)	(1,665)
Net cash (used in) received from financing activities	<u>(6,956)</u>	<u>9,351</u>
Net change in cash, cash equivalents and restricted cash	<u>(2,624)</u>	<u>(43,255)</u>
Cash, cash equivalents and restricted cash, beginning of year	<u>47,469</u>	<u>90,724</u>
Cash, cash equivalents and restricted cash, end of year	<u>\$ 44,845</u>	<u>\$ 47,469</u>

The notes beginning on page 9 are an integral part of the consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

STEWARDSHIP FOCUSED DISCLOSURES

1. Organizational Overview

Our mission

The American Cancer Society exists because the burden of cancer is unacceptably high. We are the only organization that integrates advocacy, discovery, and direct patient support to measurably improve the lives of cancer patients and their families. While cancer affects everyone, it doesn't affect everyone equally. We are working to ensure everyone has a fair and just opportunity to prevent, detect, treat, and survive cancer.

Here are some of the ways we are making progress to make the most impact possible in the fight against cancer:

- **Patient support** – We provide the latest, evidence-based cancer information; equip people to make healthy choices that can help reduce their cancer risk like eating right, staying active, and avoiding alcohol and tobacco; and develop guidelines for screening that can help detect certain cancers early and save lives.

We are available 24/7 to help people find answers and resources, whether they want to understand their diagnosis and treatment options, learn how to cope with side effects, or find transportation or a place to stay when treatment is far from home. We provide information and support to cancer patients, caregivers, and survivors through online communities and one-on-one support.

- **Discovery** – The American Cancer Society launches innovative, high-impact research to find more – and better – treatments, uncover factors that may cause cancer, and improve quality of life for people facing cancer. We fund research grants and conduct cancer research studies to help accelerate the pace of progress. We conduct equity-focused research to identify and understand issues related to cancer disparities in an effort to advance health equity among all communities.
- **Advocacy** – Through our nonprofit, nonpartisan advocacy affiliate, the American Cancer Society Cancer Action NetworkSM (ACS CAN), we fight at all levels of government to demand change from our elected officials to build healthier communities, create safer workplaces, and provide greater, more equitable access to quality medical care.

For information or support, visit [cancer.org](https://www.cancer.org) or call our 24/7 helpline at **1-800-227-2345**.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

1. Organizational overview, continued

Our mission program and mission support expenses

Our expenses fall into two categories: first, our mission program activities – which are the three areas above, and second, mission support services – expenses incurred to support our mission activities – which include: our internal audit function, which assesses and monitors our accounting, internal control and technology processes; our finance function organization, which processes enterprise-wide financial and constituent transactions; our technology processes; general infrastructure costs; and the costs of fundraising. Other than our volunteer base, our largest resource – our staff – are allocated in both categories depending on their role, set of activities and effort reporting. Expenses for our community office locations, including rent are also allocated based on our staff effort reporting. Other expenses are allocated based on various methods including the underlying purpose of transactions. For the years ended December 31, 2021 and 2020, our mission expenses were allocated to these two areas as follows:

	<u>2021</u>		<u>2020</u>	
Mission program expenses	\$ 481,531	80 %	\$ 442,499	76 %
Mission support expenses	120,417	20	139,749	24
Total	<u>\$ 601,948</u>	<u>100 %</u>	<u>\$ 582,248</u>	<u>100 %</u>

Covid-19 impact

In 2020, COVID-19 had an adverse and significant impact in our ability to operate our mission programs and raise funds to support those programs. To help fight the pandemic, we closed Hope Lodges, suspended patient assistance programs, reduced research grant spending, closed Discovery Shops and cancelled in person fundraising events. Our closures of Discovery Shops and cancellation of in-person fundraising events caused a substantial decline in revenue resulting in our implementing cost containment measures. We made a strategic decision to reduce and realign our physical and staffing footprint aimed at increasing our overall mission impact. In the first half of 2021, COVID-19 continued its damaging impact. Upon the second half of 2021, the Society began to re-emerge operations by reopening our Hope Lodges and Discovery Shops, increasing patient support services and research grants, as well as hosting in-person fundraising events. As a result, our revenue and expenses increased in 2021 compared to 2020.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations

Investments

To ensure consistency with our mission objectives, we do not invest in securities of any tobacco companies.

We maintain a pool of investments for the primary purpose of providing liquidity for daily operating needs while protecting principal and preserving the real (inflation-adjusted) purchasing power of the portfolio. The overall short-term investment balance is targeted based on our projected daily and monthly net cash flows and is generally intended to ensure all operating needs are met throughout the year without tapping into our long-term investments.

We also maintain an investment pool with a long-term investment horizon to preserve the real (inflation-adjusted) purchasing power while providing a relatively predictable, constant and stable stream of earnings. The pool utilizes a diversified approach to asset allocation comprised of target ranges for the various asset classes. Together, all our investment pools, at fair value, were as follows:

	<u>December 31, 2021</u>	<u>December 31, 2020</u>
Global equity	\$ 214,234	\$ 160,608
Impact venture capital	20,588	10,980
Real estate	43,314	37,742
Liquid alternatives	72,362	72,421
Multi-asset credit	81,827	70,904
Core fixed income	167,840	302,318
Treasury inflation-protected security	80,117	83,347
Short duration fixed income	231,514	74,758
Cash	79,120	58,509
	<u>\$ 990,916</u>	<u>\$ 871,587</u>

Gift annuity investments

Sufficient assets are maintained to meet the annuity requirements stipulated by the various state laws. We are required to hold reserves related to our gift annuity program based on the laws in certain states in which we solicit these gifts. Such reserves totaled \$28,102 and \$25,483 at December 31, 2021 and 2020, respectively, and are included in gift annuity investments in the accompanying consolidated balance sheets.

Planned gifts (Bequests and Beneficial Interest in Trusts)

We are the beneficiary of planned gifts under bequests, other testamentary documents, trusts and similar deferred contributions. The assets from a bequest or a contribution may be given directly to us or may be put in the care of a trustee, with the Society being designated as having a full or partial beneficial interest in the trust ("BIT"). Certain gifts are considered split-interest agreements whereby we receive benefits that are shared, or split, with either the donor or third-party beneficiaries. Depending on the number and mortality of any third-party beneficiaries, we may not receive cash for our interest in the BIT's for a number of years. During the years ended December 31, 2021 and 2020, approximately 30% and 60% of our revenue from bequests was cash and 70% and 40% will be received in future years, respectively.

The management of the assets within the various trusts, including the purchase and sale decisions, is performed by the respective trustee, and we have no ability to control or influence these decisions. Distributions from these trusts are based on the terms of the underlying trust agreement that generally require that the investment income be distributed on at least an annual basis.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations, continued

Use of net assets

Included in net assets without donor restrictions at December 31, 2021 and 2020 is \$233,054 and \$229,884, respectively, that is our net investment in fixed assets and is not available to spend on current operations. Also included in net assets without donor restrictions at December 31, 2021 and 2020 is \$16,869 and \$20,862 designated by the Board for BrightEdge, our Philanthropic Impact Fund. Our goal is to invest in companies that accelerate access to lifesaving and therapeutic technologies for the patients and families we serve.

Net assets with donor restrictions result from contributions of assets whose use by the Society is specified by our donors through time and specific purpose restrictions. For net assets with time restrictions, the assets are not restricted for a specific purpose by the donor. Instead, the donor's restriction on our use of those assets may be met with the passage of time if the time restriction is not in perpetuity. Included in net assets with donor restrictions at December 31, 2021 and 2020 is \$493,422 and \$456,975, respectively; that we have not yet received in cash and which will be used for our mission program services once received. The use of net assets with donor restrictions as of December 31, 2021 and 2020 has been limited by our donors for the following purposes:

	With Donor Restrictions	
	2021	2020
Mission programs:		
Patient support:		
Hope Lodge facilities	\$ 120,265	\$ 137,432
Other	79,629	64,392
Discovery	167,830	153,363
Advocacy	5,747	5,422
Across mission programs:		
Time restrictions (primarily planned giving including perpetual trusts and endowments)	345,000	314,023
Specific geographic locations	46,901	43,441
Other mission program and mission support services	6,453	2,989
Total	<u>\$ 771,825</u>	<u>\$ 721,062</u>

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations, continued

Financial assets available for use

The Society structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Additionally, the Society generally invests its cash in excess of weekly requirements in short-term investments. The Society invests its remaining operating assets in a fully diversified mix of investment vehicles designed to provide continued liquidity, preserve capital, and grow corpus.

Given the comprehensive nature of the Society's mission and reliance on donor restricted contributions to fund ongoing, annual programs, the Society defines "available for general expenditures" as all net assets without donor restrictions excluding amounts for deferred compensation, custodial assets, and illiquid investments and including net assets with donor restrictions and expected spend down on endowments anticipated to be spent within one year of the balance sheet date.

The Society's Board of Directors has implemented a liquidity policy that requires the Society to maintain available financial assets equal to between six months and ten months of the annual general expenditures which is calculated based on several factors, including anticipated cash outlays for operating activities. Compliance with the policy is reviewed quarterly by the Board.

The Society's financial assets available within one year of the balance sheet date for general expenditures are as follows:

	2021	2020
Financial assets without donor restrictions		
Investments, cash, and cash equivalents	\$ 724,435	\$ 620,288
Current receivables, net	4,775	7,130
Current bequests receivable	96,792	52,194
Total financial assets without donor restrictions	826,002	679,612
Less deferred compensation, custodial, and other illiquid investments	(138,696)	(89,500)
Less amounts unavailable to management without Board approval		
Amount remaining in cash and investments designated for BrightEdge	(16,869)	(20,862)
Total amounts unavailable to management	(155,565)	(110,362)
Total financial assets available to management for general expenditures	670,437	569,250
Add funds with donor restrictions expected to be spent within 12 months December 31, 2021	43,748	30,533
Total financial assets managed for liquidity	\$ 714,185	\$ 599,783

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations, continued

Research and other grant programs

As part of our commitment to the fight against cancer, we actively provide grants to improve both the prevention and detection of cancer. The total amount of our future payments under research and other program grants as of December 31, 2021 and 2020 is \$201,385 and \$168,939, respectively. The present value of our future payments as of December 31, 2021 and 2020 is \$198,673 and \$165,689, respectively. The discount at December 31, 2021 of \$2,712 will be recognized as grants for mission program services expense in 2022 through 2026. As of December 31, 2021, our future payments are as follows:

Payable in the next:		
12 months	\$	84,432
13 - 24 months		58,667
25 - 36 months		37,379
37 - 48 months		19,245
49 - 60 months		1,662
Discount		<u>(2,712)</u>
Total	\$	<u>198,673</u>

Operating leases

We maintain a physical presence in a significant number of communities we serve across the country and many of these locations are subject to operating lease agreements. Additionally, telecommunication systems related to our National Cancer Information Center are leased. Some of these leases are subject to payment escalations and expire on various dates through 2026. Our future minimum annual lease payments under leases with terms that are not cancellable are as follows as of December 31, 2021:

Payable in the next:		
12 months	\$	9,811
13 - 24 months		7,690
25 - 36 months		6,655
37 - 48 months		4,678
49 - 60+ months		<u>6,998</u>
Total	\$	<u>35,832</u>

Rental expense under operating leases was \$18,269 and \$27,967 for the years ended December 31, 2021 and 2020, respectively.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations, continued

Debt

We have financed certain properties based on market conditions and cash flow needs at the time of financing. Our outstanding debt, subject to certain loan covenants, as of December 31, 2021 and 2020 is as follows:

Type	Issuer	Maturity Date	Interest rate	Balance at 12/31/2021	Balance at 12/31/2020	Collateral 12/31/2021
Note Payable	TD Bank, N.A.	2027	2.46%	27,630	29,549	New York City Hope Lodge facility, net book value of \$25,139 and all assets constituting general revenues
Note Payable	Alliance Finance Fund	2044	1.00%	-	9,750	
Note Payable	SCC SUB-CDE 10,LLC	2047	1.00%	9,602	9,602	Jackson Hope Lodge Facility, net book value of \$7,929
Notes Payable	SEFCU	2022	2.00% - 5.75%	283	308	Not Applicable
Total				<u>\$ 37,515</u>	<u>\$ 49,209</u>	

Our future principal payments are as follows:

Payable in the next:	
12 months	\$ 2,294
13 - 24 months	2,011
25 - 36 months	2,143
37 - 48 months	2,372
49 - 60 months	2,377
Thereafter	26,318
Total	<u>\$ 37,515</u>

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

2. Liquidity considerations, continued

Retirement funding

We have a variety of retirement benefit strategies that cover nearly all our employees. We sponsor a defined benefit pension plan (the "Plan") through which we provide benefits that are based on years of service and certain averages of compensation. We fund the plan on a quarterly basis based on estimates of annual funding levels stated by pension requirements, which are enforced by regulatory agencies. In general, these requirements stipulate that our plan be funded at a level of 60% to continue to pay full benefits to retired individuals. As of January 1, 2022, and 2021, the plan was funded at 100% and 100%, respectively, based on regulatory funding levels.

We also sponsor a defined contribution plan with benefits based on individual employee salary deferrals and a related matching amount by the Society, subject to a maximum. Our matching amounts totaled \$8,714 and \$5,624 for the years ended December 31, 2021 and 2020, respectively. We sponsor a Supplemental Executive Retirement Plan (SERP) for certain participants whose income exceeds the maximum income that can be considered under the defined benefit pension plan. We have segregated short-term investments sufficient for payment of benefits under this plan.

In addition, we have an unfunded postretirement benefit plan for post-retirement medical, dental, and life insurance coverage for certain employees hired prior to 1995, subject to deductibles, co-payment provisions, and other limitations. We paid \$1,559 and \$1,605 for these benefits from our general assets during the years ended December 31, 2021 and 2020, respectively.

We expect to contribute approximately \$12,793, to all our defined benefit plans over the next 12 months. The Plan and the SERP were frozen to new participants and participants are no longer earning benefits for service under the Plan. See Note 10 for additional information.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

3. Contributed services, merchandise, and other non-cash contributions

We recorded contributed services related to the communication of mission program and fundraising messages through various media. We also have valued and recorded contributed services provided by scientific peer reviewers for the extramural research grant process. Moreover, we received in-kind contributions of advertising production, magazine space, public service announcements, and in-store advertising materials from various retail and professional organizations. Our volunteers contribute significant amounts of time to our program services, administration, and fundraising and development activities; however, the consolidated financial statements do not reflect the value of these contributed services because they do not meet the recognition criteria prescribed by generally accepted accounting principles.

Total contributed services, merchandise, and other in-kind contributions for the years ended December 31, 2021 and 2020 are as follows:

	2021	2020
Media communication and production services	\$ 19,103	\$ 13,680
Discovery Shops	22,191	14,268
Wigs	-	1,882
Guestroom program	-	1,827
Peer review services (approximately 548 and 504 volunteers donated 17,810 and 18,144 hours, respectively)	1,128	1,991
Other in-kind contributions	5,721	6,448
Total contributed services, merchandise, and other in-kind contributions at fair value	<u>\$ 48,143</u>	<u>\$ 40,096</u>

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

OTHER REQUIRED DISCLOSURES

4. Significant accounting policies

Principles of consolidation

Our consolidated financial statements include the accounts of the American Cancer Society, Inc. and our other subsidiaries, which are all separately incorporated and designated exempt from taxation by IRC Section 501(a). All significant intra-Society accounts and transactions have been eliminated.

Accounting for contributions

Contributions that are restricted by donors for a specific purpose are recorded as increases in net assets with donor restrictions. When the specific purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as use of amounts restricted by donors for specified purpose or time. Contributions restricted by donors for a stipulated period are recorded as increases in net assets without donor restrictions if the stipulated period restriction ends in the reporting period in which the revenue is recognized. When the stipulated period ends in a subsequent reporting period, the contributions are first recorded as increases in net assets with donor restrictions and are subsequently reclassified in the reporting period when the stipulated period ends. Contributions restricted by donors for a specific purpose that contain certain conditions are recognized as increases in net assets without donor restrictions if both the specific purpose is accomplished and the conditions are met in the same year in which the revenue is recognized.

Contributed merchandise and other in-kind contributions, including merchandise remaining in inventory at year end, are reported as contributions at their estimated fair values when received or when an unconditional promise to give has been made. Gifts of long-lived assets received without stipulations about how long the donated asset must be used are reported as revenue without donor restrictions. Gifts of cash or other assets with a purpose restriction to acquire long-lived assets are reported as an increase to donor restricted net assets and released from restriction when the asset is acquired and placed in service unless the gift also is accompanied by an explicit donor time restriction, in which the asset is released over the life of the time restriction.

Advertising costs

Our advertising costs are expensed as incurred and were \$44,163 and \$27,337 for the years ended December 31, 2021 and 2020, respectively.

Bequests receivable

We consider a bequest unconditional when the probate court declares the testamentary instrument valid and the proceeds are measurable.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

4. Significant accounting policies, continued

Beneficial interests in trusts

Nonperpetual BIT's are initially recognized as donor restricted public support (bequest or contribution revenue, depending upon the initial source of the gift) at fair value, based on our interest in the fair value of the underlying trust assets at the time of the gift. Any subsequent adjustments to the nonperpetual BIT's are recorded as a change in value of split-interest agreements.

Perpetual trusts are initially recorded as net assets with donor restrictions public support (bequest or contribution revenue, depending on the initial source of the gift) at fair value, based on our interest in the fair value of the underlying trust assets at the time of the gift. Subsequent changes to a trust's fair value are a change in value of split interest agreements and reported as net unrealized gains or losses on perpetual trusts within net assets with donor restrictions in the consolidated statements of activities. Income received from the trusts is reported as net assets with donor restrictions or net assets without donor restrictions, depending on the existence or absence of donor-imposed restrictions.

We also may be the beneficiary of interests in trusts and other assets in situations where we have not been notified of our interest. Our interest may be conditional or revocable, or the value of our interest may not be readily ascertainable. In such circumstances, no revenue has been recorded.

Cash and cash equivalents

We consider all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents - with the exception of cash held for reinvestment - which is included in investments and gift annuity investments, as appropriate.

Fair value of financial instruments

The three levels of the fair value hierarchy are described as follows:

Level 1 Inputs to the valuation methodology are unadjusted readily available quoted prices for identical assets or liabilities in active markets that we have the ability to access.

Level 2 Inputs to the valuation methodology include:

- Quoted prices for similar assets or liabilities in active markets;
- Quoted prices for identical or similar assets or liabilities in inactive markets;
- Inputs other than quoted prices that are observable for the asset or liability; or
- Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for a substantial portion of the full term of the asset or liability.

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Our financial instruments consist of cash and cash equivalents, investments, receivables, gift annuity investments, bequests receivable, beneficial interests in trusts, research and other program grants payable, accounts payable and accrued expenses, and debt. Investments, beneficial interest in trusts, gift annuity investments and the related obligations are recorded at their fair values.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

4. Significant accounting policies, continued

Fixed assets

Fixed assets are recorded at cost for purchased items and fair value for contributed items.

If donors contribute long-lived assets with stipulations as to how long the assets must be used or with any other restrictions, we report those contributions as net assets with donor restrictions.

Depreciation expense is recognized on a straight-line basis over the estimated useful lives of the assets, as follows:

Buildings	20 to 40 years
Leasehold improvements	Lesser of term of the lease or estimated life of the improvement
Furniture, fixtures, equipment, computer software, and other capitalized assets	3 to 10 years
Equipment under capital leases	Lesser of the term of the lease or estimated life of the equipment

Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the expected amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenditures during the reporting period. Actual results may differ from those estimates.

The following are assumptions we used to estimate certain reported amounts, which are not required to be measured at fair value on a recurring basis, as of December 31, 2021 and 2020. The assumptions used to estimate amounts, which are required to be measured at fair value on a recurring basis are included in Note 8.

Discount rates:

	December 31, 2021	December 31, 2020
Pledges receivable	1.65% to 4.20%	1.65% to 4.20%
Research and other program grants payable	0.36% to 2.84%	0.36% to 2.84%

Pledges receivable consist of donor promises to give and are recognized in the period received with an allowance or discounted amount provided for estimated uncollectible amounts. The total amount of the discount for pledges as of December 31, 2021 and 2020 is \$910 and \$578, respectively. The research and other program grants payable discount at December 31, 2021 and 2020 is \$2,712 and \$3,250 respectively.

Our cost-reimbursement grant programs are subject to independent audit under federal regulations and review by grantor agencies. These audits and reviews could result in the disallowance of expenditures under the terms of the grant or reductions of future grant funds. Based on prior experience, we believe that any costs ultimately disallowed would not materially affect our consolidated financial position.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

4. Significant accounting policies, continued

Income taxes

Consistent with our mission, we have received a determination letter from the Internal Revenue Service that indicates we are exempt from income tax under Section 501(a) of the U.S. Internal Revenue Code as an organization described in section 501(c)(3). Further, the Society has been classified as an organization that is not a private foundation under IRC Section 509(a) and, as such, contributions to the Society qualify for deduction as charitable contributions. However, income generated from activities unrelated to the Society's exempt purpose is subject to tax under IRC Section 511. The Society did not have a material unrelated business income tax liability for the years ended December 31, 2021 and 2020. The Society believes that it has taken no significant uncertain tax positions.

Change in presentation

Certain reclassifications have been made to the prior year's information to conform to the current year presentation. Our prior year's consolidated statements of activities and consolidated statements of functional expenses have been updated to the revised functional categories that more accurately reflect our operating structure.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

4. Significant accounting policies, continued

Adoption of new accounting pronouncements

While there are many new accounting pronouncements issued that the Society has adopted or will be adopting in the near future, the following pronouncements have significant disclosure requirements that impact our consolidated financial statements.

As of January 1, 2020, the Society adopted the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2014-09, *Revenue from Contracts with Customers (Topic 606)*, as amended. ASU 2014-09 applies to exchange transactions with customers that are bound by contracts or similar arrangements and establishes a performance obligation approach to revenue recognition. Results for reporting the 2020 fiscal year are presented under ASC 606, using the modified retrospective method for contracts not completed at adoption. There was no material impact to the consolidated financial statements as a result of the adoption.

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)*, which when effective will require organizations to recognize assets and liabilities on the balance sheet for the rights and obligations created by the leases. A lessee will be required to recognize assets and liabilities for leases with terms that exceed twelve months. The standard will also require disclosures to help financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The standard is effective for our reporting period ending December 31, 2022, and we are in the process of finalizing the adoption of the standard.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*, which requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected. The guidance is effective for the Society for fiscal years beginning after December 15, 2022. We are currently evaluating the potential impact on our consolidated financial statements and do not expect it to have a material impact on our financial results.

In May 2019, the FASB issued ASU 2019-05, *Financial Instruments (Topic 326)*, which will allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The election must be applied on an instrument-by-instrument basis for eligible instruments. The guidance is effective for the Society for fiscal years beginning after December 15, 2022. We are currently evaluating the potential impact on our consolidated financial statements and do not expect it to have a material impact to our financial results.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958), Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets* to clarify the presentation and disclosure of contributed nonfinancial assets. Contributed nonfinancial assets must be presented as a separate line item in the statement of activities which is separate from contributions of cash and other financial assets. The standard will also require contributed nonfinancial assets recognized within the statement of activities to be disaggregated by category that depicts the type of contributed nonfinancial assets. The disclosures include qualitative information about whether the assets were monetized or utilized, the policy about monetizing rather than utilizing the contributed assets, the valuation technique for measuring fair value and the principal market used for fair value measurement. The guidance is effective for fiscal years beginning after June 15, 2021, with early adoption permitted. We are currently evaluating the potential impact on our consolidated financial statements.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

5. Activities with joint costs

For the years ended December 31, 2021 and 2020, we incurred expenses to conduct activities that had both fundraising appeals, as well as mission program and management and general components (joint activities). Those joint activities included direct mail, telecommunications, and other constituent relationship activities. Our costs of conducting those joint activities were allocated as follows:

	<u>2021</u>	<u>2020</u>
Patient support	\$ 64,857	\$ 72,757
Management and general	2,065	5,365
Fundraising	24,294	28,084
Total	<u>\$ 91,216</u>	<u>\$ 106,206</u>

6. Exchange transactions

Exchange transactions are reciprocal transfers in which each party receives and sacrifices something of approximate commensurate value, as opposed to a nonreciprocal transaction (i.e., a contribution), in which a donor provides resources to support our mission and expects to receive nothing of commensurate value in return. Costs of exchange transactions that benefit the recipient of the exchange and are not directly related to our mission are reported as exchange expenses. Costs related to exchange transactions that directly benefit or support our mission are reported in mission program or mission support expenses.

Exchange transaction income and expenses are netted and included in other gains (losses) in the accompanying consolidated statements of activities and are included in their natural classifications on the consolidated statements of functional expenses. Exchange transaction income and expenses are as follows as of December 31, 2021 and 2020:

	Exchange Income		Exchange Expenses	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
Special events	\$ 16,986	\$ 6,513	\$ 16,986	\$ 6,510
Discovery Shop	22,855	14,719	39,150	29,769
Sales to third parties	3,665	5,116	-	-
Other	9,376	4,203	-	45
	<u>\$ 52,882</u>	<u>\$ 30,551</u>	<u>\$ 56,136</u>	<u>\$ 36,324</u>

As shown in the table above, we conduct special events in which a portion of the gross proceeds paid by the participant represents payment for the direct cost of the benefits received by the participant at the event. Unless a verifiable, objective means exists to demonstrate otherwise, the fair value of meals and entertainment provided at special events is measured using an estimate based upon historical costs. The direct costs of the special events that ultimately benefit the donor, rather than us, are recorded as exchange transaction income and exchange transaction expense. All proceeds received by us in excess of the direct costs are recorded as special events revenue in our consolidated statements of activities.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

7. Fixed assets

Our fixed assets are as follows as of December 31, 2021 and 2020:

	<u>2021</u>	<u>2020</u>
Land	\$ 22,680	\$ 26,451
Buildings and leasehold improvements	340,836	351,648
Furniture, fixtures, equipment, and other capitalized assets	24,255	37,625
Computer software	33,164	35,696
Construction in progress	25,279	31,669
Less: accumulated depreciation and amortization	<u>(175,639)</u>	<u>(203,996)</u>
Net fixed assets	<u>\$ 270,575</u>	<u>\$ 279,093</u>

Depreciation expense, including expenses on assets used in exchange transactions for the years ended December 31, 2021 and 2020 was \$14,676 and \$15,664, respectively.

8. Fair value measurement

Refer to Note 4 for a description of our fair value of financial instrument policy.

The asset and/or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Our valuation techniques maximize the use of observable inputs and minimize the use of unobservable inputs.

The availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the transfer is reported at the beginning of the reporting period.

The significance of transfers between levels was evaluated based upon the nature of the financial instrument and size of the transfer relative to total net assets. For the years ended December 31, 2021 and 2020, there were no significant transfers in or out of Levels 1, 2, or 3.

Following is a description of the valuation methods we used for assets and liabilities measured at fair value. There have been no changes in the valuation methods.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

Global equity, including securities listed on domestic and international exchanges, are principally valued at the regular trading session closing price on the exchange or market in which such securities are principally traded, on the last business day of each period presented, using the market approach.

Impact venture capital investments are generally valued using the market approach, based upon the relative interests of each participating investor (including each participant), market prices and assumptions.

Investments in real estate are valued using the market approach, based upon the relative interests of each participating investor (including each participant), in the fair value of the underlying net assets of each limited partnership.

Investments in liquid alternatives are generally valued using the market approach, based upon the relative interest of each participating investor (including each participant), in the fair value of the underlying net assets of each of the respective liquid alternative.

Multi-asset credit investments are valued based upon evaluated prices provided by independent pricing services when such processes are believed to reflect the fair market value of such securities using the income approach, as well as regular trading session closing price on the exchange or market, using the market approach.

Core fixed income investment valuations, including corporate bonds, commercial paper, and government agency obligations are based upon evaluated prices provided by independent pricing services when such processes are believed to reflect the fair market value of such securities using the market approach, as well as the use of the income approach in absence of a discoverable market.

Treasury Inflation-Protected securities (TIPs) investments or inflation-indexed securities are based upon evaluated prices provided by independent pricing services and adjusted by the consumer price index when such processes are believed to reflect the fair market value of such securities using the market approach, as well as the use of the income approach in absence of a discoverable market.

Short duration fixed income investment valuations are based upon evaluated prices provided by independent pricing services, when such processes are believed to reflect the fair market value of such securities using the income approach.

Cash and cash equivalents are principally valued at the regular trading session closing price on the exchange or market in which such funds are principally traded, on the last business day of each period presented, using the market approach.

Nonperpetual trusts, included on the consolidated balance sheets as beneficial interest in trusts, are recorded at their estimated fair value based on the present value of our estimated future cash receipts from the trust. Future cash receipts are based on an income approach (present value techniques) using internally developed models. Assumptions are made regarding the expected rate of return on the investments in the trust, the discount rate, and the expected mortality of the individual(s) if the termination of the agreement is dependent on life expectancy. An expected rate of return on the investments in the trusts is estimated using historical investment returns for various relevant market indices for the estimated asset allocation of the nonperpetual trusts. For the years ended December 31, 2021 and 2020, based on then-current financial market conditions, we estimated the present value of nonperpetual trusts using an investment return rate (net of trustee fees and other expenses) of 9.70% and 6.24% respectively, and a discount rate of 9.70% and 6.24%, respectively, commensurate with the risks involved.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

The expected mortality is estimated using the 2012 Individual Annuity Reserving Mortality Tables for one single or two life beneficiary charitable gifts. Each of these calculations is based on the fair value of the underlying assets of the trust. As trust statements are not received as of year-end for some trust, the fair value of the underlying assets is adjusted based on changes in the relevant market indices from the date of the trustee statement to year-end that correlate to the estimated asset allocation of the underlying assets. As the fair value of these trusts is derived from internal estimates of the present value of our interest in the underlying assets, incorporating market data when available, the amounts ultimately received could differ from the amounts reflected in the historical financial statements.

Perpetual trusts, included on the consolidated balance sheets as beneficial interests in trusts, are recorded at fair value based on our interest in the fair value of the underlying trust assets. As trust statements are not received as of year-end for some trusts, the most recent fair value of the underlying assets is adjusted based on changes in the relevant market indices from the date of the trustee statement to year-end that correlate to the estimated asset allocation of the underlying assets.

Our gift annuity obligation is recorded at fair value based on Level 3 inputs and other relevant market data based on the present value of our estimated future cash outflows. For the years ended December 31, 2021 and 2020, the assumptions used in the valuation of the annuity liability include mortality in accordance with the 2012 Individual Annuity Reserving Mortality Tables and a discount rate of 1.93% and 2.90%, respectively for all annuities, compounded annually, net of expenses. These rates are commensurate with the risks associated with the ultimate payment of the obligation. We have elected fair value accounting for our gift annuity obligations.

The preceding valuation methods described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting dates.

The following tables set forth by level, within the fair value hierarchy, our assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

Assets	Financial assets and liabilities measured at fair value as of December 31, 2021			
	Level 1	Level 2	Level 3	Total
Investments, current				
Cash and cash equivalents	\$ 10,081	\$ 69,039	\$ -	\$ 79,120
Core fixed income	-	59,368	-	59,368
Total investments, current	\$ 10,081	\$ 128,407	\$ -	\$ 138,488
Gift annuity investments, at fair value				
Global equity	\$ 28,191	\$ -	\$ 82	\$ 28,273
Core fixed income	6,130	7,313	-	13,443
Total gift annuity investments, at fair value	\$ 34,321	\$ 7,313	\$ 82	\$ 41,716
Investments				
Global equity	\$ 138,560	\$ -	\$ 506	\$ 139,066
Global equity measured at net asset value*	-	-	-	46,895
Impact venture capital	240	-	18,474	18,714
Impact venture capital at net asset value*	-	-	-	1,874
Real estate measured at net asset value*	-	-	-	43,314
Liquid alternatives measured at net asset value*	-	-	-	72,362
Multi-asset credit	-	8,512	-	8,512
Multi-asset credit measured at net asset value*	-	-	-	73,315
Core fixed income	7,635	87,394	-	95,029
Treasury inflation-protected security	-	80,117	-	80,117
Short duration fixed Income	21,833	209,681	-	231,514
Total investments	\$ 168,268	\$ 385,704	\$ 18,980	\$ 810,712
Beneficial interests in trusts	\$ -	\$ -	\$ 406,638	\$ 406,638
Liabilities				
Gift annuity obligations	\$ -	\$ -	\$ 13,614	\$ 13,614

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

Assets	Financial assets and liabilities measured at fair value as of December 31, 2020			
	Level 1	Level 2	Level 3	Total
Investments, current				
Cash and cash equivalents	\$ 57,259	\$ -	-	\$ 57,259
Core fixed income	75,581	-	-	75,581
Total investments, current	<u>\$ 132,840</u>	<u>\$ -</u>	<u>-</u>	<u>\$ 132,840</u>
Gift annuity investments, at fair value				
Cash and cash equivalents	\$ 1,250	\$ -	-	\$ 1,250
Global equity	24,202	-	69	24,271
Core fixed income	6,073	7,866	-	13,939
Total gift annuity investments, at fair value	<u>\$ 31,525</u>	<u>\$ 7,866</u>	<u>\$ 69</u>	<u>\$ 39,460</u>
Investments				
Global equity	\$ 77,814	\$ -	1,521	\$ 79,335
Global equity measured at net asset value*	-	-	-	57,002
Impact venture capital	1,218	-	8,930	10,148
Impact venture capital at net asset value*	-	-	-	832
Real estate measured at net asset value*	-	-	-	37,742
Liquid alternatives measured at net asset	-	-	-	72,421
Multi-asset credit	-	70,904	-	70,904
Core fixed income	43,186	169,612	-	212,798
Treasury inflation-protected security	1,107	82,240	-	83,347
Short duration fixed Income	74,758	-	-	74,758
Total investments	<u>\$ 198,083</u>	<u>\$ 322,756</u>	<u>\$ 10,451</u>	<u>\$ 699,287</u>
Beneficial interests in trusts	<u>\$ -</u>	<u>\$ -</u>	<u>371,852</u>	<u>\$ 371,852</u>
Liabilities				
Gift annuity obligations	<u>\$ -</u>	<u>\$ -</u>	<u>13,972</u>	<u>\$ 13,972</u>

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

* In accordance with *Fair Value Measurement (Topic 820)*, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheets.

The table below provides a summary of changes in the fair value of our Level 3 financial assets and liabilities measured on a recurring basis for the years ended December 31, 2021 and 2020:

December 31, 2021	Global equity	Beneficial interest in trusts	Gift annuity obligation
Balance, beginning of year	\$ 10,520	\$ 371,852	\$ 13,972
Purchases (sold)	5,822	(10,572)	-
Unrealized gains (losses)	3,803	31,231	-
Other	(1,083)	14,127	(358)
Balance, end of year	<u>\$ 19,062</u>	<u>\$ 406,638</u>	<u>\$ 13,614</u>

December 31, 2020	Global equity	Beneficial interest in trusts	Gift annuity obligation
Balance, beginning of year	\$ 8,378	\$ 355,309	\$ 13,299
Purchases (sold)	2,850	-	-
Unrealized gains (losses)	1,180	13,497	-
Other	(1,888)	3,046	673
Balance, end of year	<u>\$ 10,520</u>	<u>\$ 371,852</u>	<u>\$ 13,972</u>

The unrealized gains (losses) related to the beneficial interest in trusts and the gift annuity obligations are included in the change in value of split interest agreements in the accompanying consolidated statements of activities. The unrealized gains (losses) related to the global equity are included in the investment income. The unrealized gains (losses) related to assets still held at December 31, 2021 and 2020 were \$31,231 and \$13,497, respectively.

The following tables set forth additional disclosures for the fair value measurement of investments in certain entities that calculate net asset value per share (or its equivalent) as of December 31, 2021 and 2020:

Investment type	December 31, 2021		December 31, 2020	
	Fair value	Unfunded commitments	Fair value	Unfunded commitments
Global equity	\$ 46,895	\$ -	\$ 57,002	\$ -
Impact venture capital	1,874	-	832	-
Real estate	43,314	-	37,742	-
Liquid alternatives	72,362	-	72,421	-
Multi-asset credit	73,315	-	-	-
Total	<u>\$ 237,760</u>	<u>\$ -</u>	<u>\$ 167,997</u>	<u>\$ -</u>

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

8. Fair value measurement, continued

Global equity are mainly composed of common stocks in various business sectors. The fair values of the investments within the fund are based on the current market prices or quotations readily available on the day of valuation. Requests for common stock redemption may be made on each business day based upon the net asset value per unit and the closing market value on the valuation date of the investments bought or sold. The fund's investment objective is to approximate as closely as practicable, before expenses, the performance of the Standard & Poor's 500® Tobacco Free Index over the long term.

The real estate holdings are recorded at net asset value, which approximates fair value as determined by independently conducted appraisals of the properties. The appraisals of the real estate holdings have been prepared with consideration to the income, cost, and sales comparison approaches of estimating property value. Requests for redemption may be made by delivering a redemption notice at least 45 days in advance. The investment objective is to give investors a robust core real estate portfolio that provides a diversified portfolio of the highest quality assets, both durable and growing income with highly liquid assets and a conservative risk profile. There are no unfunded commitments.

The liquid alternatives are private investment funds that target to provide superior risk-adjusted returns through diversified portfolio investments. The investments' net asset values are determined by valuation methods of external pricing, internal modeling, price estimates, comparable analysis, or official closing price on the principal exchange markets for such investments as of the valuation point. Investment capital can be redeemed at the end of any calendar quarter with maximums ranging from 20% to 25% depending on shareholder class.

9. Endowment

Interpretation of relevant law

As a New York corporation, we are subject to and have interpreted the New York Prudent Management of Institutional Funds Act (NYPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, we classify as net assets with donor restrictions: (a) the original value of gifts to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund, and (d) the donor-restricted endowment fund that we have not fulfilled the donor-stipulated purpose and/or the required time period has not been elapsed. For the amounts that are not restricted in perpetuity, we have appropriated those amounts for expenditure in a manner consistent with the standard of prudence prescribed by NYPMIFA.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

9. Endowment, continued

Endowment net asset composition by type and changes in endowments	With Donor Restrictions	
	2021	2020
Endowment net assets, beginning	\$ 142,587	\$ 106,990
Investment return, net	11,856	16,902
Endowment cash additions	3,251	23,066
Reclassification of restrictions	199	92
Appropriation of endowment assets for expenditure	(6,548)	(4,463)
Endowment net assets, ending	\$ 151,345	\$ 142,587

Funds with deficiencies

From time to time, due to adverse market conditions, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or relevant law requires us to retain as a fund of perpetual duration. Deficiencies of this nature are reported in net assets with donor restrictions, to the extent there are accumulated gains available to absorb such loss, or otherwise in net assets without donor restrictions. Deficiencies of this nature that are reported in net assets without donor restrictions were \$0 and \$28 as of December 31, 2021 and 2020, respectively.

Return objectives and risk parameters

We have adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain the purchasing power of the endowment assets. Under this policy, the endowment assets are invested in a manner that is intended to produce results that exceed the price and yield results of relevant market indices while assuming a moderate level of investment risk.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

9. Endowment, continued

Spending policy

We considered the following factors in developing our spending policy with regard to donor-restricted endowment funds: (1) the duration and preservation of the various funds, (2) our mission and donor-restricted endowment funds, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and appreciation of investments, (6) our other resources, (7) our investment policies, and (8) where appropriate, alternatives to spending from the donor-restricted funds and the possible effects of those alternatives.

Unless the donor has specified otherwise, 4% of the three-year rolling average fair value of an endowment is available for spending each year, to the extent of a donor restricted endowment's cumulative undistributed earnings. In addition, the difference between the actual total return each year and the spending percentage is charged or credited to net assets without donor restrictions or net assets with donor restrictions (depending on the donor's instructions regarding the use of investment income or relevant law). We believe a spending policy is necessary to carry out the statutorily prescribed standard of ordinary business care and prudence and uses a spending rate of 4% in order to maintain the purchasing power of the endowment. Endowment assets consist of:

	Current Allocation		Target Allocation		
	2021	2020	Minimum	Target	Maximum
Global equity	55 %	51 %	45 %	55 %	65 %
Real estate	9	8	5	10	15
Liquid alternatives	10	12	5	10	15
Multi-asset credit	13	8	10	15	20
Core fixed Income	8	17	0	5	10
Treasury inflated protected securities	5	4	0	5	10
	100 %	100 %		100.00 %	

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans

We maintain a noncontributory defined benefit pension plan (Plan) and SERP that were frozen in 2016 to new participants and participants are no longer earning benefits for service performed under the Plan and SERP. The current strategic mix for the Plan's assets is a blended exposure to equity and debt market risk. The Plan employs an active management strategy that has historically generated returns in excess of established benchmarks and places greater emphasis on manager skills to produce excess return while employing various risk mitigation strategies to reduce volatility. The Plan's assets at December 31, consist of:

	Current Allocation		Target	+/- Bands
	2021	2020		
Global equity	30 %	33 %	33 %	10 %
Multi-asset credit	8	8	9	5
Liquid alternatives	10	11	9	5
Real estate	7	5	6	5
Core fixed income	43	42	43	5
Cash	2	1	0	
	<u>100 %</u>	<u>100 %</u>	<u>100.00 %</u>	

Targets are as a percentage of the total return-seeking portfolio. Bands around targets are as of a % of the total Plan.

We employ a "building block approach" in determining the long-term rate of return for plan assets. Historical markets are studied and long-term historical relationships between equity and debt are preserved, consistent with the widely accepted capital market principle that assets with higher volatility generate a greater return over the long run. Current market factors such as inflation and interest rates are evaluated before long-term capital market assumptions are determined. The long-term portfolio return is established with proper consideration of diversification and rebalancing. Peer data and historical returns are reviewed to check for reasonability and appropriateness. While the approach gives appropriate consideration to recent fund performance and historical returns, the assumption is primarily a long-term prospective rate.

We accrue the cost of providing postretirement benefits for medical, dental, and life insurance coverage over the active service period of employees and are amortizing the unrecognized transition obligation over 20 years. Medical trend rates do not apply as the plans are on fixed payment amounts.

We utilize a spot rate yield curve to estimate the pension benefit obligation and net periodic benefit costs, which provides an accurate measurement of interest costs by applying the spot rate that could be used to settle each projected cash flow individually.

Information related to our Plan, SERP, and postretirement benefit plan at December 31, 2021 and 2020 and the related changes during the years then ended are as follows:

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

December 31, 2021	Retirement Benefits	Postretirement Nonpension Benefits	Total Retirement & Postretirement Benefits
Change in benefit obligation			
Benefit obligation at beginning of year	\$ 761,605	\$ 44,806	\$ 806,411
Service cost	-	64	64
Interest cost	14,110	752	14,862
Actuarial gain	(10,057)	(3,644)	(13,701)
Plan participant contributions	-	437	437
Benefits paid	(115,182)	(1,996)	(117,178)
Benefit obligation at end of year	\$ 650,476	\$ 40,419	\$ 690,895
Change in plan assets			
Fair value of plan assets at beginning of year	\$ 593,420	\$ -	\$ 593,420
Actual expenses paid	(4,057)	-	(4,057)
Actual return on plan assets	36,475	-	36,475
Employer contributions	10,000	1,558	11,558
Plan participant contributions	-	438	438
Benefits paid	(115,182)	(1,996)	(117,178)
Fair value of plan assets at end of year	\$ 520,656	\$ -	\$ 520,656
Funded status and amounts recognized in our balance sheet in employee retirement benefits			
	\$ (129,820)	\$ (40,419)	\$ (170,239)
Supplemental Retirement Benefits			\$ (407)
Weighted average actuarial assumptions			
Discount rate:			
Net periodic pension service cost	N/A	3.05%	
Net periodic pension interest cost	1.91%	1.73%	
Benefit obligation	2.70%	2.48%	
Expected return on plan assets	6.00%	N/A	
Rate of compensation increase	N/A	4.13%	
Amounts not yet recognized in net periodic pension costs			
Unrecognized prior service credit at beginning of year	\$ -	\$ -	-
Change in prior service cost	-	-	-
Unrecognized prior service credit at end of year	\$ -	\$ -	-
Unrecognized actuarial losses at beginning of year	\$ 199,717	\$ 11,219	\$ 210,936
Change in actuarial losses	(38,822)	(4,826)	(43,648)
Unrecognized actuarial losses at end of year	\$ 160,895	\$ 6,393	\$ 167,288
Supplemental Retirement Benefits			\$ 31

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

December 31, 2021	Retirement Benefits	Postretirement Nonpension Benefits	Total Retirement & Postretirement Benefits
Amounts recognized as a reduction (increase) to unrestricted net assets			
Amounts recognized as a reduction to unrestricted net assets at			
beginning of year	\$ 199,717	\$ 11,219	\$ 210,936
Change in prior services credit	-	-	-
Change in actuarial losses	(38,822)	(4,826)	(43,648)
Amounts recognized as a reduction to unrestricted net assets at end of year	<u>\$ 160,895</u>	<u>\$ 6,393</u>	<u>\$ 167,288</u>
Supplemental Retirement Benefits			\$ 37
Components of net periodic benefit cost			
Service cost	\$	\$ 64	\$ 64
Interest cost	14,110	752	14,862
Expected return on plan assets	(34,263)	-	(34,263)
Administrative expenses	3,890	-	3,890
Amortization of:			-
Unrecognized prior service cost (credit)	-	-	-
Unrecognized actuarial losses (gains)	3,777	1,182	4,959
Settlement expense (credit)	22,943	-	22,943
Net periodic benefit (credit) cost	<u>\$ 10,457</u>	<u>\$ 1,998</u>	<u>\$ 12,455</u>
Accumulated benefit obligation	\$ 650,476	\$ 40,419	\$ 690,895
Supplemental Retirement Benefits			\$ 40
Estimated future benefits payable in the			
12 months	\$ 36,850	\$ 2,793	\$ 39,643
13 - 24 months	35,670	2,745	38,415
25 - 36 months	35,996	2,692	38,688
37 - 48 months	34,701	2,632	37,333
49 - 60 months	34,304	2,570	36,874
Thereafter	164,937	11,813	176,750

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

December 31, 2020	Retirement Benefits	Postretirement Nonpension Benefits	Total Retirement & Postretirement Benefits
Change in benefit obligation			
Benefit obligation at beginning of year	\$ 733,808	\$ 41,877	\$ 775,685
Service cost	-	91	91
Interest cost	20,313	1,120	21,433
Actuarial loss	73,347	2,839	76,186
Plan participant contributions	-	542	542
Benefits paid	(65,863)	(2,147)	(68,010)
Retiree drug subsidy	-	484	484
Benefit obligation at end of year	\$ 761,605	\$ 44,806	\$ 806,411
Change in plan assets			
Fair value of plan assets at beginning of year	\$ 569,100	\$ -	\$ 569,100
Actual expenses paid	(4,611)	-	(4,611)
Actual return on plan assets	94,794	-	94,794
Employer contributions	-	1,605	1,605
Plan participant contributions	-	542	542
Benefits paid	(65,863)	(2,147)	(68,010)
Fair value of plan assets at end of year	\$ 593,420	\$ -	\$ 593,420
Funded status and amounts recognized in our balance sheet in employee retirement benefits			
	\$ (168,185)	\$ (44,806)	\$ (212,991)
Supplemental Retirement Benefits			\$ (428)
Weighted average actuarial assumptions			
Discount rate:			
Net periodic pension service cost	N/A	3.57%	
Net periodic pension interest cost	2.86%	2.77%	
Benefit obligation	3.34%	3.21%	
Expected return on plan assets	6.25%	N/A	
Rate of compensation increase	N/A	4.13%	
Amounts not yet recognized in net periodic pension costs			
Unrecognized prior service credit at beginning of year	\$ -	\$ (3,006)	\$ (3,006)
Change in prior service cost	-	3,006	3,006
Unrecognized prior service credit at end of year	\$ -	\$ -	\$ -
Unrecognized actuarial losses at beginning of year	\$ 203,328	\$ 9,346	\$ 212,674
Change in actuarial losses	(3,611)	1,873	(1,738)
Unrecognized actuarial losses at end of year	\$ 199,717	\$ 11,219	\$ 210,936
Supplemental Retirement Benefits			\$ 36

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

December 31, 2020	Retirement Benefits	Postretirement Nonpension Benefits	Total Retirement & Postretirement Benefits
Amounts recognized as a reduction (increase) to unrestricted net assets			
Amounts recognized as a reduction to unrestricted net assets at			
beginning of year	\$ 203,328	\$ 6,340	\$ 209,668
Change in prior services credit	-	3,006	3,006
Change in actuarial (gains)losses	(3,611)	1,873	(1,738)
Amounts recognized as a reduction to unrestricted net assets at end of year	<u>\$ 199,717</u>	<u>\$ 11,219</u>	<u>\$ 210,936</u>
Supplemental Retirement Benefits			\$ 19
Components of net periodic benefit cost			
Service cost	\$	\$ 91	\$ 91
Interest cost	20,313	1,120	21,433
Expected return on plan assets	(34,561)	-	(34,561)
Administrative expenses	5,800	-	5,800
Amortization of:			-
Unrecognized prior service cost (credit)	-	(3,006)	(3,006)
Unrecognized actuarial losses	3,845	966	4,811
Settlement expense	11,691	484	12,175
Net periodic benefit (credit) cost	<u>\$ 7,088</u>	<u>\$ (345)</u>	<u>\$ 6,743</u>
Accumulated benefit obligation	\$ 761,605	\$ 44,806	\$ 806,411
Supplemental Retirement Benefits			\$ 428
Estimated future benefits payable in the next:			
12 months	\$ 43,053	\$ 2,940	\$ 45,993
13 - 24 months	42,123	2,868	44,991
25 - 36 months	40,984	2,813	43,797
37 - 48 months	40,364	2,755	43,119
49 - 60 months	39,651	2,690	42,341
Thereafter	188,224	12,305	200,529

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

We expect to contribute \$10,000 to the Plan and approximately \$2,793 to our postretirement benefit plan over the next 12 months. The actuarial losses included in net assets without donor restrictions related to our Plan that we expect to recognize in net periodic pension cost over the next 12 months are \$2,704. The actuarial losses included in net assets without donor restrictions related to our postretirement benefit plan that we expect to recognize in net periodic benefit cost is \$472 within the same period.

A description of the valuation methods we used for assets measured at fair value is available in Note 8.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

10. Employee retirement benefit plans, continued

The fair value of the Plan's assets at December 31, 2021 and 2020 by asset category is as follows:

Financial assets measured at fair value on a recurring basis as of December 31, 2021				
	Level 1	Level 2	Level 3	Total
Global equity	\$ 119,391	\$ -	\$ -	\$ 119,391
Global equity measured at net asset value*	-	-	-	37,621
Multi-asset credit	40,993	102	-	41,095
Liquid alternatives measured at net asset value*	-	-	-	53,809
Real estate measured at net asset value*	-	-	-	38,019
Core fixed income	18,976	203,714	-	222,690
Cash	8,031	-	-	8,031
Total investment assets, at fair value	<u>\$ 187,391</u>	<u>\$ 203,816</u>	<u>\$ -</u>	<u>\$ 520,656</u>

Financial assets measured at fair value on a recurring basis as of December 31, 2020				
	Level 1	Level 2	Level 3	Total
Global equity	\$ 124,409	\$ -	\$ -	\$ 124,409
Global equity measured at net asset value*	-	-	-	73,251
Multi-asset credit	-	48,413	-	48,413
Liquid alternatives measured at net asset value*	-	-	-	62,504
Real estate measured at net asset value*	-	-	-	31,415
Core fixed income	7,129	242,388	-	249,517
Cash	3,911	-	-	3,911
Total investment assets, at fair value	<u>\$ 135,449</u>	<u>\$ 290,801</u>	<u>\$ -</u>	<u>\$ 593,420</u>

* In accordance with *Fair Value Measurement (Topic 820)*, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheets.

AMERICAN CANCER SOCIETY, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2021 and 2020
(Dollars in thousands)

11. Commitments and contingencies

We are a party to legal claims arising in the course of our normal business activities. Although the ultimate outcome of these claims cannot be ascertained at this time, we believe that none of these matters, when resolved, will have a material effect on our net assets.

12. Subsequent events

Management has evaluated the need for disclosures and/or adjustments resulting from subsequent events through June 9, 2022, the date the consolidated financial statements were issued. During this period, increasing costs and inflation along with tight labor markets and geopolitical uncertainty have impacted our expenses in 2022. In addition, significant market volatility and downturn in the first part of 2022 have impacted the value of our invested assets. While we have been able to offset these impacts through cost controls, diversified revenue and investment portfolios, and management decisions, continued negative impacts could adversely affect our ability to raise funds for and carry out our critical work of improving the lives of cancer patients and their families. We will continue to closely monitor these events and take mitigating actions as appropriate.

Supplementary Information and Reports
and Schedule Required by the
Uniform Guidance

American Cancer Society, Inc.
Schedule of Expenditures of Federal Awards
For the 12 months ending December 31, 2021

<u>Federal Grantor/Grant Title</u>	<u>Assistance Listing</u>	<u>Pass Through Entity Identifying No.</u>	<u>Federal Expenditures</u>	<u>Expenditures to Subrecipients</u>
U.S. Department of Health & Human Services				
Direct Program:				
Comprehensive Cancer Control Technical Assistance and Training Program	93.427	n/a	\$ 815,786	\$ -
Total Comprehensive Cancer Control Technical Assistance and Training Program (93.427)			815,786	-
Direct Program:				
Immunization Cooperative Agreements	93.268	n/a	373,902	-
Pass Through from State of Illinois				
Immunization Cooperative Agreements	93.268	no. 051880200H	45,912	-
Pass Through from North Dakota Department of Health				
Immunization Cooperative Agreements	93.268	G19.1054	7,023	-
Total Immunizations Cooperative Agreements (93.268)			426,837	-
Direct Program:				
Centers for Disease Control & Prevention - Category C: Hospital Systems	93.421	n/a	2,148,142	118,500
Total Centers for Disease Control & Prevention - Category C: Hospital Systems (93.421)			2,148,142	118,500
Research and Development Cluster				
Pass Through from Beckman Research Institute of the City of Hope				
National Institutes of Health - Cancer Cause & Prevention Research	93.393	R01CA202712-05	77,349	-
Pass Through from Mt. Sinai				
National Institutes of Health - Cancer Cause & Prevention Research	93.393	0255-2961-4609	3,767	-
Pass Through from Joan & Sanford I. Weill Medical College of Cornell University				
National Institutes of Health - Cancer Cause & Prevention Research	93.393	204253-1	25,073	-
Pass Through from Fred Hutchinson University				
National Institutes of Health - Cancer Cause and Prevention Research	93.393	subaward no.: 0001030418	15,508	-
Pass Through from IARC				
National Institutes of Health - Cancer Cause and Prevention Research	93.393	NCI Grant No. U19CA203654	12,678	-
Pass Through from Case Western Reserve University				
National Institutes of Health - Cancer Centers Support Grants	93.397	5P5OCA150964-08- REVISED	19,921	-
Pass Through from Washington University				
National Institutes of Health - Cancer Centers Support Grants	93.397	WU-21-270	20,834	-
Pass Through from Emory University				
National Aeronautics and Space Administration - Science	43.001	80NSSC21K0507	948	-
Pass Through from University of Southern California				
National Institutes of Health - Family Smoking Prevention and Tobacco Control Act Regulatory Research	93.077	143300400	34,856	-
Pass Through from Fred Hutchinson Cancer Research Center				
Department of Agriculture - Agriculture and Food Research Initiative (AFRI)	10.310	1090682	7,621	-

See notes to Schedule of Expenditures of Federal Awards

American Cancer Society, Inc.
Schedule of Expenditures of Federal Awards
For the 12 months ending December 31, 2021

<u>Federal Grantor/Grant Title</u>	<u>Assistance Listing</u>	<u>Pass Through Entity Identifying No.</u>	<u>Federal Expenditures</u>	<u>Expenditures to Subrecipients</u>
Pass Through from University of Iowa				
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	Account No. 0011L00002eqmY5QAI	22,978	-
Pass Through from Emory University				
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	A529560	15,694	-
Total Research and Development Cluster			257,227	-
Other Programs				
Pass Through from State of West Virginia				
Centers for Disease Control and Prevention - Investigations & Technical Assistance	93.898	G210085	22,636	-
Pass Through from Arizona Department of Health				
Centers for Disease Control and Prevention - Investigations & Technical Assistance	93.898	CTR053813	14,057	-
Total Centers for Disease Control and Prevention - Investigations & Technical Assistance (93.898)			36,693	-
Pass Through from University of South Carolina				
Centers for Disease Control and Prevention - Organized Approaches to Increase Colorectal Cancer Screening	93.800	5NU58DP006137-05-00	123,453	-
Pass Through from Michigan Department of Health & Human Services				
Centers for Disease Control and Prevention - Organized Approaches to Increase Colorectal Cancer Screening	93.800	Improving Colon Cancer Screening	26,724	-
Pass Through from North Carolina Department of Health & Human Services				
Centers for Disease Control and Prevention - Organized Approaches to Increase Colorectal Cancer Screening	93.800	Contract No. 41626	102,479	-
Total Centers for Disease Control and Prevention Organized Approaches to Increase Colorectal Cancer Screening (93.800)			252,656	-
Total US Department of Health and Human Services			3,928,772	118,500
Pass Through from Nevada				
Corporation For National and Community Service - Volunteer Generation Fund	94.021	n/a	2,500	-
United States Department of the Treasury				
Pass Through from State of Alaska				
COVID-19 - Coronavirus Relief Fund	21.019	Coronavirus Nonprofit Relief Fund	27,023	-
Pass Through from State of Maryland				
COVID- 19 - Coronavirus Relief Fund	21.019	Coronavirus Nonprofit Relief Fund	50,000	-
Total Coronavirus Relief Fund (21.029)			79,523	-
Total US Department of Treasury			79,523	-
Total Expenditures of Federal Awards			\$ 4,016,864	\$ 118,500

American Cancer Society, Inc.
Notes to the Schedule of Expenditures of Federal Awards
for the Year Ended December 31, 2021

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Schedule of Expenditures of Federal Awards includes the federal grant activity of the American Cancer Society, Inc. ("the Society"), for the year ended December 31, 2021. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the schedule presents only a selected portion of operations of the Society, it is not intended to and does not present the financial position, results and activities, changes in net assets or cash flows of the Society.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Schedule of Expenditures of Federal Awards is prepared on the accrual basis of accounting. The Society did not elect to use the 10% de minimis indirect cost rate permitted by the Uniform Guidance.

3. CONTINGENCIES

These Federal programs are subject to financial and compliance audits by grantor agencies which, if instances of material noncompliance are found, may result in disallowed expenditures and affect the Society's continued participation in specific programs. The amount, if any, of expenditures which may be disallowed by the grantor agencies cannot be determined at this time, although the Society expects such amounts, if any, to be immaterial.



Ernst & Young LLP
Suite 1000
55 Ivan Allen Jr. Boulevard
Atlanta, GA 30308

Tel: +1 404 874 8300
Fax: +1 404 817 5589
ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Management and The Board of Directors
American Cancer Society, Inc.

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of the American Cancer Society, Inc. ('the Society'), which comprise the consolidated balance sheet as of December 31, 2021, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated June 9, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Society's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control. Accordingly, we do not express an opinion on the effectiveness of the Society's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Society's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with



those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

June 9, 2022



Ernst & Young LLP
Suite 1000
55 Ivan Allen Jr. Boulevard
Atlanta, GA 30308
Tel: +1 404 874 8300
Fax: +1 404 817 5589
ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Management and The Board of Directors
American Cancer Society, Inc.

Report of Independent Auditors on Compliance for Each Major Federal Program

Opinion on the Major Federal Program

We have audited the American Cancer Society, Inc.'s ('the Society') compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on the Society's major federal program for the year ended December 31,2021. The Society's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Society complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31,2021.

Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Society and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for the major federal program. Our audit does not provide a legal determination of the Society's compliance with the compliance requirements referred to above.



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Society's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Society's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Society's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Society's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Society's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Society's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

June 9, 2022

**American Cancer Society, Inc.
Schedule of Findings and Questioned Costs
for the Year Ended December 31, 2021**

Section I—Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

 yes X **no**

Significant deficiency(ies) identified?

 yes X **none reported**

Noncompliance material to financial statements noted?

 yes X **no**

Federal Awards

Internal control over major federal program:

Material weakness(es) identified?

 yes X **no**

Significant deficiency(ies) identified?

 yes X **none reported**

Type of auditor’s report issued on compliance for major federal program:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 yes X **no**

Identification of major federal programs:

Assistance Listing number(s)

93.427

Name of federal program

Comprehensive Cancer Control Technical Assistance and Training Program

Dollar threshold used to distinguish between Type A and Type B programs:

\$ 750,000

Auditee qualified as low-risk auditee?

X **yes** **no**

American Cancer Society, Inc.
Schedule of Findings and Questioned Costs (continued)
for the Year Ended December 31, 2021

Section II—Financial Statement Findings

Findings: No matters were identified

Section III—Federal Award Findings and Questioned Costs

Findings: No matters were identified



June 7, 2022

Summary Schedule of Prior Audit Finding

The American Cancer Society, Inc. (“the Society”), respectively submits the following Summary Schedule of Prior Audit Finding for the year ended December 31, 2021.

Finding 2019-001 Reporting – Financial

Assistance Listing Number: 93.421

Program Name: Centers for Disease Control & Prevention (CDC) - Category C: Hospital Systems

Granting Agency: Centers for Disease Control & Prevention, Department of Health and Human Services

Responsible Contact: Lorance Hui

Status: Corrective action was taken

Finding 2020-001 Reporting – Financial

Assistance Listing Number: 93.421

Program Name: Centers for Disease Control & Prevention (CDC) - Category C: Hospital Systems

Granting Agency: Centers for Disease Control & Prevention, Department of Health and Human Services

Responsible Contact: Lorance Hui

Status: Corrective action was taken

stay well | get well | find cures | fight back | cancer.org | 1.800.227.2345